Skip to content

Co-profiling of exosomal proteins and microRNAs using single microbead confinement for breast cancer diagnosis.

Sep 2026 · Biosensors & bioelectronics · Vol 314, pp. 119196 · 0 citations · 40 references
Medicine

TL;DR

A single microbead-confined dual-mode detection system that selectively captures TEXs for concurrent quantification of protein and miRNA biomarkers and is the first demonstration of a universal PNA modification strategy that harnesses a DNA mediator to prevent AuNPs self-aggregation.

Abstract

Tumor-derived exosomes (TEXs) hold immense promise as biomarkers for cancer diagnosis, but sensitive and accurate identification is hindered by their intrinsic heterogeneity and extreme scarcity. Co-profiling of exosomal protein and microRNA (miRNA) at the single-molecule level may greatly enhance the precision of cancer diagnosis and prognosis. Herein, we present a single microbead-confined dual-mode detection system that selectively captures TEXs for concurrent quantification of protein and miRNA biomarkers. Exosomal proteins are quantified by measuring fluorescence signal concentrated on a single microbead-based enrichment platform. After on-bead lysis, individual miRNA is recognized by the two peptide nucleic acids (PNAs) to form a strict one-to-one correspondence with the intense light-scattering signal of gold nanoparticles (AuNPs), enabling single-molecule counting analysis. Through comprehensive profiling, a panel of four conjoint biomarkers achieve the highest diagnostic accuracy of 98.33%, outperforming any individual markers or alternative combinations. Importantly, this is the first demonstration of a universal PNA modification strategy that harnesses a DNA mediator to prevent AuNPs self-aggregation. This platform can also be adapted to other cancers by simply changing the aptamers and PNAs to target corresponding biomarkers, showing significant potential for advancing exosome-based liquid biopsies and accelerating the development of next-generation clinical diagnostic tools.

View source

Similar papers

Aug 2026

Single-Exosome EpCAM Heterogeneity Profiling for Breast Cancer Diagnosis and Progression Monitoring.

Exosomes are nanoscale vesicles that are attractive for liquid biopsy, but most methods deliver ensemble averages and obscure how surface biomarkers vary across individual vesicles. We develop a single-particle impact electrochemistry (SPIE) assay to profile epithelial cell adhesion molecule (EpCAM) on single exosomes....

Mei-Hong Peng, Dan-Ping Xu, Yuan-Yuan Zhang et al. · 0 citations
Open access Aug 2026

Multiplexed Profiling of Individual Extracellular Vesicles Reveals Lung Cancer‐Associated Protein Signatures

ABSTRACT Lung cancer is frequently diagnosed after curative treatment windows have narrowed, creating a need for minimally invasive biomarkers that report tumor development at earlier stages. Extracellular vesicles (EVs) are promising analytical targets because they carry molecular cargo from their originating cells, b...

Mi Hyeon Cho, Yein Chung, Yoonjeong Choi et al. · 0 citations
Sep 2026

Machine Learning-Assisted Multiplex Profiling of Plasma-Derived Exosomal miRNAs for Alzheimer's Disease Classification.

Accurate diagnosis of Alzheimer's disease (AD) remains challenging due to its multifactorial nature and the limitations of current diagnostic methods. Exosome-derived microRNAs (miRNAs) have emerged as promising minimally invasive biomarkers, owing to their stability in peripheral biofluids and their ability to reflect...

Yeonwoo Jeong, Jinyoung Kim, Ji-Na Lee et al. · 0 citations
Open access Aug 2026

Orthogonal DNA barcoding enables subpopulation-resolved extracellular vesicle miRNA profiling

Extracellular vesicle–associated microRNAs (EV-miRNAs) hold promise for liquid biopsy, but their clinical utility is hindered by EV heterogeneity. Here, we report DEEPER, a DNA-encoded orthogonal recognition platform for selective barcoding of tumor-derived EV subpopulations and in situ miRNA profiling. DEEPER uses fou...

Ye Zhang, Yi-Tong Zhu, Yu Zhang et al. · 1 citation
Sep 2026

Precise Mutation Detection in Low-Abundance Tumor-Derived Extracellular Vesicles via Microfluidic Immunomagnetic Reversible Affinity Capture.

The MIRACLE platform is developed, an integrated system combining microfluidic magneto-controllable reversible affinity capture with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for efficient, multiplexed detection of tumor-derived EV DNA mutations.

Xing Xu, Shan-Shan Liang, Heng-Kai Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.